STOCK TITAN

BioStem Technologies (BSEM) Stock News, Apr-Jul 2025

BSEM NASDAQ

BioStem Technologies reports developments tied to its regenerative medicine business, which develops, manufactures and commercializes perinatal tissue allograft products used by clinicians across wound care and other specialties. Company updates commonly cover financial results, conference calls, clinical research presentations, and product portfolio activity involving brands such as Neox, Clarix, VENDAJE and American Amnion.

BioStem news also includes governance and compliance appointments, board changes, audited financial statement publication, and integration of completed asset acquisitions that expand its surgical and wound-care product offerings. Its disclosures describe proprietary BioRetain, CryoTek and SteriTek processing technologies, AATB-accredited quality systems, and operations aligned with current Good Tissue Practices and current Good Manufacturing Processes.

Rhea-AI Summary

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived wound care products, has responded to CMS's proposed changes for skin substitute reimbursement in CY 2026. The company supports the reform efforts aimed at addressing Medicare spending in this category.

CEO Jason Matuszewski emphasized their commitment to working with stakeholders during the 60-day comment period to optimize reimbursement methodology. The company is conducting randomized controlled trials (RCTs) for their BioREtain® technology across multiple indications, with initial results expected later this year.

Additionally, BioStem is progressing with its Form 10 filing and plans to provide updates on its Nasdaq uplisting during Q2 2025 earnings call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.05%
Tags
none
-
Rhea-AI Summary

BioStem Technologies (OTC: BSEM), a leading MedTech company specializing in placental-derived products for advanced wound care, announces that Chairman and CEO Jason Matuszewski will present at the Advanced Wound Care Summit's Investor Forum on July 15, 2025, at 2:00 PM ET in Boston.

The presentation, titled "Invest in the Future of Advanced Wound Care with BioStem Technologies," will showcase the company's core allograft business and growth opportunities. BioStem leverages its proprietary BioREtain® processing method and maintains AATB accreditation and FDA registration for its Pompano Beach facility. The company's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, American Amnion and American Amnion AC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
conferences
-
Rhea-AI Summary
BioStem Technologies (OTC: BSEM) has completed enrollment of 71 patients in its clinical trial evaluating BioREtain Amnion Chorion (BR-AC) for treating diabetic foot ulcers (DFUs). The multicenter, randomized controlled trial, initiated in Q4 2024 across 11 U.S. sites, aims to demonstrate superior wound healing compared to standard care over 12 weeks. Topline results are expected in Q4 2025. The study is part of three ongoing clinical trials for BioREtain-processed allografts. The DFU market represents a significant opportunity, with 2.2 million patients treated in 2023 and annual treatment costs between $9-13 billion in the U.S. According to APMA, approximately 15% of diabetic patients develop foot ulcers, with 14-24% potentially requiring amputation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.10%
Tags
Rhea-AI Summary
Ernst & Young LLP (EY US) has named Jason Matuszewski, CEO and Chairman of BioStem Technologies (OTC: BSEM), as an Entrepreneur Of The Year 2025 Florida Award winner. BioStem Technologies, based in Pompano Beach, Florida, is a MedTech company specializing in placental-derived allografts using their proprietary BioREtain technology for chronic wound care. The company develops and manufactures advanced wound care solutions used by clinicians nationwide. As a Florida award winner, Matuszewski advances to consideration for the National Awards at the Strategic Growth Forum in November 2025, with potential advancement to the EY World Entrepreneur Of The Year Award competition in June 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
none
-
Rhea-AI Summary
BioStem Technologies (OTC: BSEM) has provided an update on its Form 10 registration statement and SEC review process. The company anticipates filing an amended Form 10 by end of June 2025, which will include audited financials for 2023-2024 and Q1 2025 unaudited results. BioStem believes it has successfully addressed SEC's accounting comments regarding revenue treatment and fees paid to Venture Medical. The company has submitted its Nasdaq listing application and plans to uplist upon Form 10 effectiveness. BioStem Technologies specializes in developing and manufacturing placental-derived products for advanced wound care using its proprietary BioREtain processing method. The company maintains AATB accreditation and FDA registration for its Pompano Beach facility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.36%
Tags
none
-
Rhea-AI Summary

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, announces its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami. CEO Jason Matuszewski will engage in a fireside chat and one-on-one meetings.

BioStem Technologies leverages its proprietary BioREtain® processing method to develop and manufacture allografts. The company's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC® products. Their facility in Pompano Beach, Florida, is FDA registered and AATB accredited, operating under cGTP and cGMP standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
conferences
Rhea-AI Summary
BioStem Technologies (OTC: BSEM) has received Notice of Allowance from the USPTO for three new patents - two design patents and one utility patent - related to their fenestrated human placental allograft designs and compositions. The patents cover their novel BioREtain® process and unique fenestration design that allows wound exudate to pass through the graft while maintaining allograft area. This technology preserves the structural and molecular integrity of amnion and chorion tissues, enhancing wound treatment particularly for diabetic foot ulcers and dental wounds. The company's expanding patent portfolio now includes 55 issued patents and 52 pending applications. BioStem's quality management system is accredited by the American Association of Tissue Banks (AATB), and their products are processed at their FDA registered facility in Pompano Beach, Florida.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
-
Rhea-AI Summary
BioStem Technologies (OTC: BSEM) reported strong preliminary Q1 2025 financial results, with net revenue increasing 73% to $72.5 million compared to Q1 2024. The company achieved GAAP net income of $4.5 million ($0.27 per share) and Adjusted EBITDA of $7.8 million. Cash balance improved to $26.7 million from $22.8 million in December 2024. Growth was driven by strong performance of their wound care portfolio, particularly VendajeAC. The company received IRB approval for new clinical trials evaluating BioREtain Amnion Chorion for venous leg ulcers and Vendaje for diabetic foot ulcers. BioStem continues to expand its IP portfolio with 55 issued patents and 52 pending. The company is currently undergoing SEC review for its planned Nasdaq uplisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.88%
Tags
-
Rhea-AI Summary
BioStem Technologies (OTC: BSEM) announced its participation in the Symposium for Advanced Wound Care (SAWC) Spring meeting in Dallas from April 30 – May 4, 2025. The company will co-exhibit with Venture Medical, LLC to showcase their combined offerings: BioStem's placental allografts (AmnioWrap2® and Vendaje AC®) and Venture's OneViewTM platform. The event features scheduled discussions on CAMPS coverage, mobile wound care, and BioREtain® technology. Three scientific posters were accepted for presentation, highlighting clinical outcomes and research on BioStem's proprietary BioREtain® processing method. The company also announced ongoing randomized clinical trials for diabetic foot ulcers and venous leg ulcers, with results expected later in the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
Rhea-AI Summary

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived biologics for advanced wound care, has scheduled its first quarter 2025 financial results announcement for May 12, 2025.

The company will host a conference call and webcast at 4:30 PM ET, featuring presentations from CEO Jason Matuszewski and CFO Michael Fortunato. Investors can participate through:

  • North America Toll-Free: (800) 715-9871
  • International Toll: +1 (646) 307-1963
  • Conference ID: 9695874

Interested parties can register for the webcast through the provided link and stay updated by joining BioStem's distribution list and following their social media channels on X and LinkedIn.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
conferences earnings date

FAQ

What is the current stock price of BioStem Technologies (BSEM)?

BioStem Technologies (BSEM) last closed at $0.8182.

What is the market cap of BioStem Technologies (BSEM)?

The market cap of BioStem Technologies (BSEM) is approximately $15.7M.